60 Degrees Pharmaceuticals, Inc. (SXTP) News
Follow 60 Degrees Pharmaceuticals, Inc. (SXTP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
60 Degrees Pharmaceuticals seeks FDA national priority voucher for tafenoquine babesiosis sNDA
60 Degrees Pharmaceuticals submitted a request for a Commissioner’s National Priority Voucher to support an efficacy supplement to NDA 210607 for tafenoquine to treat babesiosis.Key Highlights:Original SEC Filing: 60 DEG
REGULATION | Sep 14, 2026, 08:13 PM UTC
L
60 Degrees updates investor presentation on tafenoquine sNDA path
60 Degrees Pharmaceuticals updated its investor presentation, outlining a tafenoquine strategy to pursue an sNDA for babesiosis and highlighting Q2 product revenue and July financing details.
EARNINGS | Sep 08, 2026, 08:37 PM UTC
L
60 Degrees Pharmaceuticals to present at H.C. Wainwright conference
60 Degrees Pharmaceuticals said its on-demand company presentation will be available beginning September 11, 2026 at 7:00 a.m. ET, with management available for one-on-one investor meetings during the conference.
EQUITY | Sep 03, 2026, 12:07 PM UTC
M
60 Degrees Pharmaceuticals Announces Private Placement
60 Degrees Pharmaceuticals announces private placement
EQUITY | Jul 30, 2026, 06:26 PM UTC
L
60 Degrees Pharma's B-Free Babesiosis Trial Clears Initial Safety Review, Advances After DSMB Recommendation
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent
REGULATION | Jul 01, 2026, 12:08 PM UTC